Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report serves as a notification of a transaction involving a Person Discharging Managerial Responsibility (PDMR) under the Disclosure and Transparency Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding a specific executive transaction rather than a financial results report.
Material Changes
The material change reported is the vesting of 50% of a Deferred Investment Award Plan made on May 1, 2010, for Ms. E. Walmsley. This event resulted in a cash payment entitlement of 1,632.25 pence per share for 25,776.652 notional Ordinary shares, payable on May 20, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details the notification of the PDMR transaction advised on May 2, 2014.
Investor Verification Points
- Verify the vesting schedule and payout date (May 20, 2014) for Ms. E. Walmsley's Deferred Investment Award.
- Confirm the calculation of the cash payment based on 25,776.652 notional shares at 1,632.25 pence per share.
- Note that this filing does not contain updated financial performance data for the company.